Dual specificity protein kinase
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/3'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref> | The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/3'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref> | ||
| + | |||
| + | ==3D structures of dual specificity protein kinase== | ||
| + | [[Dual specificity protein kinase 3D structures]] | ||
| + | |||
</StructureSection> | </StructureSection> | ||
==3D structures of dual specificity protein kinase== | ==3D structures of dual specificity protein kinase== | ||
| Line 17: | Line 21: | ||
**[[1z57]] – hCLK1 + himenialdizine – human | **[[1z57]] – hCLK1 + himenialdizine – human | ||
| - | **[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]] – hCLK1 + inhibitor<br /> | + | **[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]], [[6raa]], [[6q8p]], [[6q8k]], [[6i5l]], [[6i5k]], [[6i5i]], [[6i5h]], [[6fyo]], [[6ft9]], [[6ft8]] – hCLK1 + inhibitor<br /> |
**[[6g33]] – hCLK1 + iodotubercidine inhibitor<br /> | **[[6g33]] – hCLK1 + iodotubercidine inhibitor<br /> | ||
| Line 23: | Line 27: | ||
**[[3nr9]] – hCLK2<br /> | **[[3nr9]] – hCLK2<br /> | ||
| - | **[[5unp]] – hCLK2 + inhibitor<br /> | + | **[[5unp]], [[6fyl]], [[6fyk]], [[6fyi]] – hCLK2 + inhibitor<br /> |
*CLK3 | *CLK3 | ||
| Line 31: | Line 35: | ||
**[[2exe]] – hCLK3 kinase domain, phosphorylated | **[[2exe]] – hCLK3 kinase domain, phosphorylated | ||
| - | **[[2wu6]], [[2wu7]] | + | **[[2wu6]], [[2wu7]], [[6rct]], [[6fyr]], [[6fyp]], [[6ft7]] - hCLK3 kinase domain + inhibitor |
**[[3raw]] - hCLK3 kinase domain + leucettine | **[[3raw]] - hCLK3 kinase domain + leucettine | ||
| + | |||
| + | *CLK4 kinase domain | ||
| + | |||
| + | **[[6fyv]] – hCLK4 + inhibitor<br /> | ||
*TTK | *TTK | ||
| - | **[[3cek]], [[3dbq]], [[2zmc]] – hTTK kinase domain<br /> | + | **[[3cek]], [[3dbq]], [[2zmc]], [[6gvj]] – hTTK kinase domain<br /> |
**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br /> | **[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br /> | ||
**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand | **[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand | ||
| Line 43: | Line 51: | ||
**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand | **[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand | ||
| - | **[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]] - hTTK kinase domain + inhibitor | + | **[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]], [[6h3k]], [[6n6o]], [[4d2s]], [[4cva]], [[4cv9]], [[4cv8]], [[3wyy]], [[3wyx]] - hTTK kinase domain + inhibitor |
**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br /> | **[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br /> | ||
Revision as of 08:23, 18 June 2019
| |||||||||||
3D structures of dual specificity protein kinase
Updated on 18-June-2019
References
- ↑ Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene. 1998 Sep 17;17(11 Reviews):1447-55. PMID:9779990 doi:http://dx.doi.org/10.1038/sj.onc.1202251
- ↑ Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J. Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. Cancer Res. 2010 Dec 15;70(24):10255-64. PMID:21159646 doi:10.1158/0008-5472.CAN-10-2101
